RNS Number : 2830O
Stenprop Limited
29 May 2020




(Registered in Guernsey)

(Registration number 64865)

LSE share code: STP    JSE share code: STP


("Stenprop" or the "Company")




29 May 2020

Stenprop, the UK multi-let industrial ("MLI") property company listed on both the London and Johannesburg stock exchanges, will announce its financial results for the year ended 31 March 2020 on 12 June 2020.

A webinar for investors and analysts will be held at 9.30am UK time and 10.30am (SA time) on 12 June 2020 via Zoom conference.  For those wishing to join the webinar, please register prior to or on the day of the webinar using this link:  https://bit.ly/3c1jiy8  

For further information:

Stenprop Limited                                                                                                                    44(0)20 3918 6600

Paul Arenson (paul.arenson@stenprop.com)

Julian Carey (julian.carey@stenprop.com)           

James Beaumont (james.beaumont@stenprop.com)



Numis Securities Limited (Financial Adviser)                                                                    44(0)20 7260 1000

Hugh JonathanVicki Paine

Justin Bell              


Tavistock (PR Adviser)                                                                                                           44(0)20 7920 3150

James Whitmore

James Verstringhe


Java Capital Trustees and Sponsors Proprietary Limited                                                27 (0)11 722 3050

(JSE Sponsor)


About Stenprop:

Stenprop is a Guernsey-registered UK REIT. The objective of the Company is to deliver sustainable growing income to its investors. Stenprop's investment policy is to invest in a diversified portfolio of UK multi-let industrial (MLI) properties with the strategic goal of becoming the leading MLI business in the UK. For further information, go to www.stenprop.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.